The first generation of childhood cancer survivors is now aging into their fourth and fifth decades of life, yet health risks across the aging spectrum are not well established.
INTRODUCTION
Improvement in survival rates of childhood cancer over the last half-century is one of the major achievements of modern medicine. The relative 5-year survival for children with cancer, which was less than 30% in 1960, is now over 80%. 1 There are currently more than 363,000 survivors of childhood cancer in the United States. 1 The impact of this growing number of cancer survivors is particularly apparent when one considers that one in 680 people between the ages of 20 and 50 years in the United States is a survivor of childhood cancer. 2 Previous research has documented that childhood cancer survivors are at increased risk for a broad range of serious health conditions. [3] [4] [5] [6] How-ever, it is not clear what the prevalence of adverse health conditions will be as this at-risk population ages into middle and late adulthood. Our current analysis was undertaken to address two questions that are important for the clinical care of aging childhood cancer survivors: what is the risk of future serious health problems for survivors who developed at least one serious health condition during their childhood or young adult years, and do survivors who have reached their third decade of life without developing a serious condition have an elevated risk of serious morbidity? The Childhood Cancer Survivor Study (CCSS) performed follow-up for more than 7,600 survivors and siblings older than 35 years, providing the opportunity to address these important questions in aging survivors of childhood cancer. 7, 8 
METHODS

Population
The CCSS is a multi-institutional retrospective cohort study, with longitudinal follow-up of survivors of childhood cancer who were treated at 26 institutions in the United States and Canada. Study eligibility included diagnosis of cancer before age 21 years; initial treatment between January 1, 1970, and December 31, 1986 ; and survivors had to be alive at 5 years after diagnosis of leukemia, CNS malignancy, Hodgkin lymphoma, non-Hodgkin lymphoma, Wilms tumor, neuroblastoma, soft-tissue sarcoma, or a bone tumor. A random sample of siblings of CCSS participants served as a comparison population (n ϭ 4,031). The cohort methodology and study design have been previously described in detail. 7, 9 The CCSS was approved by the institutional review boards at the 26 participating centers. Participants provided informed consent.
All participants completed a baseline survey (administered between 1994 and 1999) that included demographics, personal/family medical history, and chronic health conditions, including assessment of subsequent malignant neoplasms. A surrogate (parent, spouse, or next of kin) completed the baseline survey for survivors who died more than 5 years after diagnosis, who were under age 18 years, or who were unable to complete the survey. Sex and race/ethnicity characteristics were available from the surveys. Subsequently, there have been four additional follow-up surveys (Appendix Fig A1 [online-only] ). Study surveys can be viewed at http://ccss.stjude.org.
Health Condition Outcomes
At baseline and at subsequent follow-up evaluations, participants completed a multi-item survey, which included participant's age at onset of organ-based health conditions. Severity scoring was applied based on the Common Terminology Criteria for Adverse Events (version 4.0, National Cancer Institute), which is used to score both acute and chronic conditions in patients and survivors of cancer. 10 This system grades conditions as mild (grade 1), moderate (grade 2), severe or disabling (grade 3), life-threatening (grade 4), or fatal (grade 5). Our current analysis was restricted to conditions grades 3 to 5 that developed at least 5 years after the cancer diagnosis (thus, conditions that developed during therapy or shortly thereafter were not included). When not enough information was available to distinguish between grades, the lower grade was assigned. Subsequent malignant neoplasms, not including recurrence of the primary childhood malignancy, were initially ascertained through self-or proxy-report questionnaires and/or death certificates and were confirmed by pathology report or, when not available, other medical records. Only subsequent malignant neoplasms occurring 5 or more years after childhood cancer diagnoses were evaluated. 11, 12 For assessment of mortality, the CCSS cohort was linked with the National Death Index to ascertain date and cause of death.
Cancer diagnosis and treatment data (including chemotherapy and radiotherapy) were abstracted from medical records at the treating institutions for the 12,593 patients who provided a signed medical release. 8,13
Statistical Analysis
Cox proportional hazards models were used to compare severe, disabling, life-threatening, or fatal health conditions among survivors, versus siblings, and were reported as hazard ratios (HR) and 95% CI. Age was used as the time scale to account for the increasing risk of severe, disabling, life-threatening, or fatal health conditions owing to age. Survivors entered the analysis at an age equivalent to 5 years postdiagnosis; siblings entered at age 5 years. Because participants could have reported multiple grade 3 to 5 conditions, the models used a counting-process approach, using all reported unique conditions for each participant, and accounting for intraparticipant correlations using sandwich SE estimates. 14, 15 Separate analyses were conducted to compare overall grade 3 to 5 conditions, plus each of 13 organ systems of interest between survivors and siblings. Additional analyses compared rates of grade 3 to 5 health conditions for subgroups of survivors who received specific treatments or combinations of treatments with siblings. Finally, a supplemental multivariable analysis was undertaken among survivors to evaluate how treatment factors affected the hazards of developing grade 3 to 5 health conditions after the age of 35 years. All analyses were adjusted for sex and race/ethnicity.
To compare the HRs between age periods, age was added as a time-varying covariate, categorized in three periods (participants ages 5 to 19 years, 20 to 34 years, and 35 years and older). The interaction between age period and group provided HRs for survivors versus siblings within each age interval. Late onset of specific severe, disabling, life-threatening, or fatal health conditions was compared in additional Cox proportional hazards models, with both survivors and siblings entering at age 35 years. We completed a sensitivity analysis to evaluate the potential impact of participants dropping out from the CCSS before age 35 years and analyzed participants who, based on birth and death dates, survived past age 35 years using the Inverse Probability Censored Weighting method to weight analyses to account for differences between participants who dropped out of our study before age 35 years versus those who did not. 16 Person-years and number of events were calculated for survivors and siblings within each age period and across all ages. To calculate incidence rates (per 1,000 person-years) of severe, disabling, lifethreatening, or fatal health conditions for survivors and siblings, person-years and number of events were fit with Poisson regression models. Models based on all ages included a restricted cubic spline for age, 17 and parameter estimates from these models were used to calculate predicted incidence rates per 1,000 person-years at a median age of 31 years.
Cumulative incidence rates for each of the primary outcomes were calculated separately for survivors and siblings, with deaths other than those as a result of fatal health conditions of interest (ie, recurrence of primary cancer or external causes such as accidents, injuries, or suicide) treated as competing risk events. 18 Similar to the Cox models, age was used as the time scale with appropriately staggered age of entry to the cohort. 19 For each outcome, the cumulative incidence was computed based on time to the earliest reported age of the event of interest. In addition to unconditional curves, conditional cumulative incidence curves were evaluated, conditioning for survival free of a grade 3-5 condition up to ages 26, 35, and 45 years. P values for comparisons between cumulative incidence for survivors and siblings at specific ages were calculated using Wald tests. Data were analyzed with SAS software, version 9.3 (SAS Institute, Cary, NC) and Stata/SE 12.1 (StataCorp, College Station, TX). Abbreviations: RT, radiotherapy. Table 1 Fig A1C) and a description of nonparticipation are also included (Appendix Table A1 ). For survivors, the median age at last follow-up was 31 years (range, 5 to 58; interquartile range, 13 years), at a median of 24.5 years from primary cancer diagnosis (range, 5 to 39.3; interquartile range, 9.6 years). Of survivors, 5,604 were 35 years old or older at last follow-up. The median age at last follow-up of siblings was 34 years (range, 3 to 62; interquartile range, 14 years). Compared with siblings, survivors had an increased cumulative incidence of severe, disabling, life-threatening, or fatal health conditions ( Fig 1 [overall] ; Appendix Fig A2 , Appendix Table A2 [by primary childhood cancer diagnosis]). The increase in cumulative incidence between survivors and siblings evident at 20 years (survivors: 16.0%; 95% CI, 14.9 to 17.2; v siblings: 3.3%; 95% CI, 2.8 to 3.9; Fig 1A) increased with age (at 50 years: 53.6% of survivors; 95% CI, 51.5 to 55.6; v 19.8% of siblings; 95% CI, 17.0 to 22.7). Notably, 24-year-old survivors of childhood cancer had the same cumulative incidence of grade 3 to 5 health conditions (19.6%) as the 50-year-old siblings. Multivariable analysis confirmed that the HR for a severe, disabling, life-threatening, or fatal health condition increased for survivors 35 years old and older compared with survivors 20 to 34 years old (HR, 5.0 v 3.8; P ϭ .03; Table 2 ).
‫ء‬
RESULTS
As listed in
By age 50 years, 22.5% of survivors (95% CI, 20.7 to 24.4) had two or more severe, disabling, life-threatening, or fatal health conditions compared with 4.3% of siblings (95% CI, 3.0 to 5.8; Figs 1B and 1C). Among survivors who reached age 35 years without a previous severe, disabling, life-threatening, or fatal health condition, 25.9% experienced a new grade 3 to 5 condition within 10 years, compared with 6.0% of healthy siblings (P Ͻ .001; Figs 1D and 1E; Appendix Table A3 ).
Beyond age 35 years, survivors experienced a marked increase in cumulative incidence (Fig 2; Appendix Fig A3) and incidence rates of grade 3 to 5 cardiac events (Table 2 ) and the development of malignant neoplasms that were not observed in other organ systems. This observation remained consistent even when restricting analyses to grade 3 to 4 events (ie, excluding mortality, data not shown). Notably, at age 50 years, certain organ systems had a low cumulative incidence of severe, disabling, life-threatening, or fatal health conditions (renal: 1.8%; 95% CI, 1.3 to 2.5; pulmonary: 3.8%; 95% CI, 3.0 to 4.7).
Specific chronic conditions were assessed (Fig 3, Appendix Fig  A4) . Survivors 35 years and older experienced increased risk for first occurrence of stroke, heart attack, and congestive heart failure compared with siblings ( Fig 3) . Evidence for an increase in risk for new onset joint replacement, renal failure, blindness, gonadal failure, and lung fibrosis did not achieve statistical significance. Even beyond age 35 years, primary cancer therapy was associated with a new onset of severe, disabling, life-threatening, or fatal health conditions (any radiotherapy: HR, 5.7; 95% CI, 4.6 to 7.0; any chemotherapy: HR, 4.9; 95% CI, 4.0 to 6.0; surgery alone: HR, 1.8; 95% CI, 1.2 to 2.7; Table  3 ). In addition, survivors exposed to radiation to the chest or neck (HR, 2.8; 95% CI, 2.3 to 3.4), brain (HR, 2.1; 95% CI, 1.6 to 2.7), or total body (HR, 3.9; 95% CI, 2.3 to 6.7) and survivors who were exposed to bleomycin (HR, 1.4; 95% CI, 1.1 to 1.9) or Ն 300 mg/m 2 of anthracycline chemotherapy were at increased risk for grade 3 to 5 conditions compared with survivors not exposed to those therapies (Appendix Table A4 ).
Using the Inverse Probability Censored Weighting analysis method, we replicated our analyses for grade 3 to 5 conditions in participants who were at least 35 years old. We calculated HRs to compare survivors with siblings, for the complete age Ն 35 years cohort (Appendix Table A5 ), and subgroups defined by treatment categories (Appendix Table A6 ), and we also calculated cumulative incidence estimates after the age 35 years. Differences from our original results were generally less than a tenth of a decimal place for both HRs and cumulative incidence (these were virtually superimposable on each other).
DISCUSSION
Health outcomes research conducted over the last three decades has established that survivors of childhood cancer are at increased risk for morbidity and mortality during their childhood and young adult years, largely as a result of adverse effects of the therapies that cured their primary malignancies. [3] [4] [5] [6] 20, 21 We previously reported that for survivors of childhood cancer at a mean age of 26 years, 62% had at least one chronic health condition with about one-quarter of survivors having a severe, life-threatening, or disabling condition. 4 Others subsequently confirmed our observation of the substantial burden of morbidity experienced among young adults who had survived a childhood cancer. 20, 21 We now identify that elevated risk for severe, disabling, life-threatening, or fatal health conditions extends across the aging spectrum into the fourth and fifth decades of life, increasing significantly beyond age 35 years versus a sibling comparison population. After assessing more than 18,000 participants contributing over 388,000 person-years of time, survivors 35 years old and older were five-fold more likely than same-age, same-sex siblings to experience a new onset of a severe, disabling, life-threatening, or fatal health condition. Indeed, even as the general population ages and accumulates age-related chronic health conditions, there seems to be no point in time where the morbidity and mortality seen in a noncancer population is equivalent to that of survivors of childhood cancer.
In addition, the absolute magnitude of this burden of morbidity in middle age is striking. By age 50 years, 50% of survivors of childhood cancer will have experienced severe, disabling, or lifethreatening morbidity or death, most commonly as a result of cardiovascular, pulmonary, hepatic, renal, and gonadal dysfunction, along with the development of subsequent malignant neoplasms. Furthermore, those who survive a first new condition remain at risk for developing additional conditions, such that by 50 years old, 22.5% have had at least two and 10.1% have had three or more grade 3 to 5 events. The National Academies' Institute of Medicine (Washington, DC) has previously recommended that these survivors receive "riskbased" care. 22 Our current findings provide a compelling rationale for continuation of risk-based health care through adulthood.
These findings have important implications for cancer screening and prevention. Though the cumulative incidence of events increased across all organ systems, after age 35 years survivors had a disproportionate increase in the incidence of subsequent malignant neoplasms and cardiac events. Although the occurrence of new malignancies has been well documented, 6, 23 we now demonstrate that this profound rise in incidence occurs during an important window of vulnerability, before the age-threshold when general population screening guidelines recommend screenings to start (eg, breast cancer at age 40 years; colon cancer at age 50 years). 24, 25 This finding highlights the importance of disseminating established guidelines for follow-up care from the Children's Oncology Group. 26 Similarly, early detection of cardiomyopathy and medical intervention may mitigate progression to heart Hazard ratios and 95% CIs of survivors versus siblings for specific chronic conditions that first occurred at or after age 35 years, adjusted for age, race, and sex. CHF, congestive heart failure. failure in survivors exposed to anthracycline chemotherapy or chestdirected radiotherapy. [27] [28] [29] Finally, the risk for stroke and myocardial infarction, identified in this study to have increased more than fivefold in survivors older than 35 years, may be modified by promoting a healthy lifestyle that can reduce rates of certain traditional cardiovascular risk factors (obesity, dyslipidemia, hypertension, diabetes, and smoking). In our study, 24-year-old survivors of childhood cancer have the same cumulative incidence of grade 3 to 5 health conditions as 50-year-old siblings. In addition, survivors are known to have higher rates of physical impairment and fatigue 30-32 and early onset of age-related memory impairment, 33 which raises the question of whether exposure to systemic chemotherapy or even focal radiotherapy at a young age may accelerate the aging process. In our study, even healthy survivors (ie, no previous health condition before age 45 years) had a significant increase in risk for future conditions, indicating an underlying predisposition for early onset of poor outcomes. Mechanisms for aging such as telomere shortening, accumulation of free-radical mediated injury, and cellular senescence have been hypothesized to be operative in cancer survivors, but this has yet to be established. 34 The CCSS has uniquely provided the first systematic, longitudinal characterization of overall physical health in a large, geographically diverse population of survivors aging through middle adulthood with comparison to a sibling population. Despite these strengths, a number of limitations should be considered. First, all outcomes were selfreported, with validation of only the subsequent malignant neoplasms. Therefore, we excluded mild and moderate events from this analysis (grades 1 and 2), expecting improved validity from higher grade outcomes. Second, therapies for many childhood malignancies have evolved over time and, thus, results from this study may not be directly generalizable to more recently treated populations. However, traditional chemotherapeutics and radiotherapy continue to be the backbone of cancer treatment for most childhood malignancies. 35, 36 Finally, though analysis of a subset of the CCSS cohort that is now at least 35 years old has the potential for participation bias, the similarity between the unweighted and weighted analyses accounting for differences between participants and nonparticipants provide strong evidence that drop-out after the age 35 years has little impact on our analytic results. Comparisons of demographic distributions and cancer-related characteristics between overall participants (n ϭ 14,359) and nonparticipants have been previously published. 9 In general, participant and nonparticipants were similar regarding sex, cancer diagnosis, age at diagnosis, age at contact, and type of cancer treatment. However, the rate of nonparticipation was significantly higher among the next-of-kin of survivors who were deceased at the baseline evaluation compared with next of kin of survivors who were alive at baseline. Comparisons between those who completed baseline and those who were lost to follow-up (ie, could not be located for baseline completion) were not statistically significant except for vital status.
In summary, we have identified that risk for morbidity and mortality continues across the life span for cancer survivors and actually increases beyond age 35 years when compared with a population of siblings. By age 50 years, more than half of survivors have experienced a severe, disabling, or life-threatening event, including death. These data raise concerns for acceleration of the aging process in this population; highlight the need for longitudinal, risk-based follow-up; and identify the increasing health burden on this population as they age.
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